RightFit
Not yet recruitingNot applicable

Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

STRIDE: Evidence-Based Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
21 Years and older
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests STRIDE, a small-group program delivered through telehealth visits. It aims to help women with hormone-sensitive breast cancer cope with side effects and take their hormone-blocking medicine as prescribed after their main cancer treatment.

The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Women age 21 or older.
  • Have stage 0 through stage 3B breast cancer that grows in response to hormones (ER+/PR+).
  • Have finished main cancer treatment, such as surgery, chemotherapy, or radiation.
  • Started taking hormone-blocking pills after main cancer treatment 3 to 12 months ago.
  • Can care for yourself and are up and about for at least half of your waking hours (ECOG score of 2 or less).
  • Can read and respond in English or Spanish.
  • Rate distress about hormone-blocking treatment as 4 or higher on a scale from 0 to 10.

Who can't join

  • Have problems with thinking or memory, uncontrolled loss of touch with reality, or a serious mental illness that your cancer doctor believes would prevent you from taking part.
  • Are enrolled in another clinical trial for hormone-blocking treatment after main cancer treatment.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Female ≥ 21 years old * Diagnosis of early-stage (stages zero through stage three B; 0-IIIb), hormone receptor positive (ER+/PR+) breast cancer * Completed primary treatment (surgery, chemotherapy, and/or radiation) * Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Ability to read and respond in English or Spanish * Distress about AET ≥ 4 on a 0-10 scale Exclusion Criteria: * Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist * Enrolled in a clinical trial for AET

Study sites (2)

FL

MA